PATHWAY-2: spironolactone for resistant hypertension.
2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki 54643, Greece.
Chrysoula
C
Boutari
2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki 54643, Greece.
Konstantinos
K
Stavropoulos
2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki 54643, Greece.
Konstantinos
K
Imprialos
2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki 54643, Greece. Electronic address: michalisdoumas@yahoo.co.uk.
Micheal
M
Doumas
2nd Propedeutic Department of Internal Medicine, Aristotle University, Thessaloniki 54643, Greece.
Asterios
A
Karagiannis
D058668:Adrenergic alpha-1 Receptor Antagonists / Q000627:therapeutic use*; D058671:Adrenergic beta-1 Receptor Antagonists / Q000627:therapeutic use*; D017298:Bisoprolol / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D008297:Male; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use*; D013148:Spironolactone / Q000627:therapeutic use*
D058668:Adrenergic alpha-1 Receptor Antagonists; D058671:Adrenergic beta-1 Receptor Antagonists; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D017292:Doxazosin; D017298:Bisoprolol